Detection of Cystatin C biomarker for clinical measurement of renal disease by developed ELISA diagnostic kits

Journal of Translational Medicine

Gang Yao¹  Tianhao Wang²  Xiaoli Zhou³  Chao Xu¹  Renren Jiang³ 

[1] Key Laboratory for Food Safety Risk Assessment, Ministry of Health, Beijing 100021, China;Department of General Practice, Zhongshan Hospital, Fudan University, Shanghai 200433, China;School of Perfume and Aroma Technology, Shanghai Institute of Technology, Shanghai 201418, China

关键词: ELISA;    VHH;    Renal function;    Human cystatin C;    Kidney;   

Others  :  1148087
DOI  :  10.1186/1479-5876-12-205

 received in 2014-01-26, accepted in 2014-06-07,  发布年份 2014

【 摘 要 】

Background

Human cystatin C (HCC) is a potential biomarker for tubular damage and impaired renal function. It is difficult to obtain efficient paired monoclonal antibodies against HCC with low molecular to meet the requirements for clinical application The present study was to establish a stable and repeatable measurement for HCC with self-made monoclonal antibodies (McAbs) and Variable domain of heavy chain of heavy-chain antibody (VHHs) increase the sensitivity.

Methods

With hybridoma technology and phage display technology: R-HCC as a screening antigen and N-HCC as the detector for antigens to obtain the specific antibody and established an enzyme-linked immunosorbent assay for human cystatin C using self-made McAbs and VHHs.

Results

We have successfully obtained three McAbs; 5 F2, 4E4, 1E11 and four VHHs; 3-2, 3-24, 3-33 and 4-5 which were specific for HCC. The measurement of HCC was established with the self-made monoclonal antibodies and VHHs with a high sensitivity the lower limit of detection at 0.5 ng/ml and the detection range at 0.5 ~ 31.3 ng/ml.

Conclusion

Our data provides a new approach for paired antibody screening and testing of the small molecular biomarker with a single dominant epitope, with the important biological and clinical significance.

【 授权许可】

   
2014 Jiang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M, Kan S, Nakano T, Matsui S, Nomura M, Hishida H, Ozaki Y: Cystatin C in acute heart failure without advanced renal impairment. Am J Med 2009, 122:566-573.
• [2]Hollenberg NK: Renal function in the patient with hypertension. Med Clin North Am 2004, 88(1):131-140.
• [3]Yildiz G, Mağden K, Abdulkerim Y, Ozcicek F, Hur E, Candan F: Glomerular filtration rate: which method should we measure in daily clinical practice? Minerva Med 2013, 104(6):613-653.
• [4]Schnermann J, Oppermann M, Huang Y: Nephron filtration rate and proximal tubular fluid reabsorption in the Akita mouse model of type I diabetes mellitus. F1000Res 2013, 2:83-93.
• [5]Praught ML, Shlipak MG: Are small changes in serum creatinine an important risk factor? Curr Opin Nephrol Hypertens 2005, 14(3):265-270.
• [6]Bojan M, Lopez-Lopez V, Pouard P, Falissard B, Journois D: Limitations of early serum creatinine variations for the assessment of kidney injury in neonates and infants with cardiac surgery. PLoS One 2013, 8(11):e79308-e79317.
• [7]Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H: Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985, 218(5):499-503.
• [8]Lopes MB, Araújo LQ, Passos MT, Nishida SK, Kirsztajn GM, Gendoroglo MS, Sesso RC: Estimation of glomerular filtration rate from serum creatinine and cystatin C in octogenarians and nonagenarians. BMC Nephrol 2013, 14(1):265-273. BioMed Central Full Text
• [9]Simonsen O, Grubb A, Thysell H: The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985, 45(2):97-101.
• [10]Woodson BW, Wang L, Mandava S, Lee BR: Urinary Cystatin C and NGAL as early biomarkers for assessment of renal ischemia-reperfusion injury: a serum marker to replace creatinine? J Endourol 2013, 27:1510-1515.
• [11]Vega A, de Vinuesa García S, Goicoechea M, Verdalles U, Martínez-Pueyo ML, Chacón A, Quiroga B, Luño J: Evaluation of methods based on creatinine and cystatin C to estimate glomerular filtration rate in chronic kidney disease. Int Urol Nephrol 2013, 10:7-13.
• [12]Svensson-Färbom P, Ohlson Andersson M, Almgren P, Hedblad B, Engström G, Persson M, Christensson A, Melander O: Cystatin C identifies cardiovascular risk better than creatinine-based estimates of glomerular filtration in middle-aged individuals without a history of cardiovascular disease. J Intern Med 2013, 275(5):506-521.
• [13]O'Seaghdha CM, Tin A, Yang Q, Katz R, Liu Y, Harris T, Astor B, Coresh J, Fox CS, Kao WH, Shlipak MG: Association of a Cystatin C gene variant with Cystatin C levels, CKD, and risk of incident cardiovasculardisease and mortality. Am J Kidney Dis 2013, 63(1):4-6.
• [14]Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES: Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem 2003, 49(4):680-701.
• [15]Ohara G, Miyazaki K, Kurishima K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N: Serum levels of cystatin C in elderly lung cancer patients. Oncol Lett 2012, 3(2):303-306.
• [16]Sekizuka H, Akashi YJ, Kawasaki K, Yamauchi M, Musha H: Cystatin C: a better marker to detect coronary artery sclerosis. J Cardiol 2009, 54(3):359-367.
• [17]Sokol JP, Schiemann WP: Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res 2004, 2(3):183-195.
• [18]Franco MC, Nagasako SS, Machado PG, Nogueira PC, Pestana JO, Sesso R: Cystatin C and renal function in pediatric kidney transplant recipients. Braz J Med Biol Res 2009, 42(12):1225-1229.
• [19]ElShafie AI, Elghazali G, Rönnelid J, Venge P: Cystatin C as a marker of immune complex-associated renal impairment in a Sudanese population with visceral leishmaniasis. Am J Trop Med Hyg 2006, 75(5):864-868.
• [20]Angelidis C, Deftereos S, Giannopoulos G, Anatoliotakis N, Bouras G, Hatzis G, Panagopoulou V, Pyrgakis V, Cleman MW: Cystatin C: an emerging biomarker in cardiovascular disease. Curr Top Med Chem 2013, 13(2):164-179.
• [21]Flodin M, Larsson A: Performance evaluation of a particleenhanced turbidimetric cystatin C assay on the Abbott ci8200 analyzer. Clin Biochem 2009, 42(9):873-876.
• [22]Xia LH, Bing XG, An XT: Grubb A: serum cystatin C assay for the detection of early renal impairment in diabetic patients. J Clin Lab Anal 2004, 18(1):31-35.
• [23]Hellerstein S, Berenbom M, Erwin P, Wilson N, DiMaggio S: The ratio of urinary cystatin C to urinary creatinine for detecting decreased GFR. Pediatr Nephrol 2004, 19(5):521-525.
• [24]Jaafar A, Seronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I: Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. AIDS 2009, 23(2):257-259.
• [25]Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, Kim BH, Lee SH, Kim YK, Kim IJ: Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci 2011, 26(2):258-263.
• [26]Ma Y, Li Q, Wang J, Xu Z, Song C, Zhuang R, Yang K, Yang A, Jin B: Cystatin C, a novel urinary biomarker for sensitive detection of acute kidney injury during haemorrhagic fever with renal syndrome. Biomarkers 2010, 15(5):410-417.
• [27]Li F, Yan L, Lai J, Ma C, Gautam M, Fu T: Molecular cloning and mRNA expression profile of sucrose transporter gene BnSUT1C from Brassica napus L. Indian J Exp Biol 2013, 51(12):1130-1136.
• [28]Ahuja A, Sen A, Yogisharadhya R, Rajak KK, Shivachandra SB: Prokaryotic expression and purification of highly soluble partial Glycoprotein Erns of Indian strain of classical swine fever virus. Indian J Virol 2012, 23(3):397-401.
• [29]Melcher K: A modular set of prokaryotic and eukaryotic expression vectors. Anal Biochem 2000, 277:109-120.
• [30]Zhang Y, Wu S, Wang J, Wernike K, Lv J, Feng C, Zhang J, Wang C, Deng J, Yuan X, Lin X: Expression and purification of the nucleocapsid protein of Schmallenberg virus, and preparation and characterization of a monoclonal antibody against this protein. Protein Expr Purif 2013, 92:1-8.
• [31]Feng X, Liu C, Guo J, Song X, Li J, Xu W, Li Z: Recombinant expression, purification, and antimicrobial activity of a novel hybrid antimicrobial peptide LFT33. Appl Microbiol Biotechnol 2012, 95:1191-1198.
• [32]Rajamohan F, Engstrom CR, Denton TJ, Engen LA, Kourinov I, Uckun FM: High-level expression and purification of biologically active recombinant pokeweed antiviral protein. Protein Expr Purif 1999, 16:359-368.
• [33]Han K, Xu L, Yan R, Song X, Li X: Molecular cloning, expression and characterization of enolase from adult Haemonchus contortus. Res Vet Sci 2012, 92:259-265.
• [34]Liu F, Lou Y, Shi X, Wang H, Zhu X: Preparation and characterization of monoclonal antibody specific for copper–chelate complex. J Immunol Methods 2013, 387:228-236.
• [35]Bai Y, Liu Z, Bi Y, Wang X, Jin Y, Sun L, Wang H, Zhang C, Xu S: Preparation of polyclonal antibodies and development of a direct competitive enzyme-linked immunosorbent assay to detect residues of Phenylethanolamine A in urine samples. J Agric Food Chem 2012, 60:11618-11624.
• [36]Zhang J, Huang B, Yu F, Wei M, Yang G, Fu H, Jin L, Bai L, He X, Lu Z: Production and characterization of polyclonal and monoclonal abs against the RNA-binding protein QKI. Appl Biochem Biotechnol 2011, 164:283-293.
• [37]Pimpitak U, Putong S, Komolpis K, Petsom A, Palaga T: Development of a monoclonal antibody-based enzyme-linked immunosorbent assay for detection of the furaltadone metabolite, AMOZ, in fortified shrimp samples. Food Chem 2009, 116:785-791.
• [38]Lee CM, Iorno N, Sierro F, Christ D: Selection of human antibody fragments by phage display. Nat Protoc 2007, 2(11):3001-3008.
• [39]Monegal A, Ami D, Martinelli C, Huang H, Aliprandi M, Capasso P, Francavilla C, Ossolengo G, de Marco A: Immunological applications of single-domain llama recombinant antibodies isolated from a naive library. Protein Eng Des Sel 2009, 22(4):273-280.
• [40]Sladewska A, Szymańska A, Kordalska M, Lewandowska A, Kołodziejczyk AS, Paraschiv G, Przybylski M, Czaplewska P: Identification of the epitope for anti-cystatin C antibody. J Mol Recognit 2011, 24(4):687-699.
• [41]Padhy M, Kaushik S, Girish MP, Mohapatra S, Shah S, Koner BC: Serum Neutrophil Gelatinase associated Lipocalin (NGAL) and cystatin C as early predictors of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Clin Chim Acta 2014, 435:48-52.
• [42]Sagheb MM, Namazi S, Geramizadeh B, Karimzadeh A, Oghazian MB, Karimzadeh I: Serum cystatin C as a marker of renal function in critically ill patients with normal serum creatinine. Nephro urol Mon 2014, 6(2):e15224-e15230.
• [43]Inker LA, Okparavero A: Cystatin C as a marker of glomerular filtration rate: prospects and limitations. Curr Opin Nephrol Hypertens 2011, 20(6):631-639.
• [44]Rossi M, Campbell K, Johnson DW, Stanton T, Haluska BA, Hawley CM, Dimeski G, Mcwhinney BC, Ungerer Jacobus PJ, Kaisar OM, Isbel NM: Uremic Toxin Development in Living Kidney Donors: A Longitudinal Study. Transplantation 2014, 97(5):548-554.
• [45]Shlipak MG, Mattes MD, Peralta CA: Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis 2013, 62(3):595-603.